MindWalk (HYFT) Q3 2026 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Thu, March 12, 2026 astatine 11:39 AM CDT 23 min read

Image source: The Motley Fool.

Thursday, March 12, 2026 astatine 10:30 a.m. ET

• Chief Executive Officer — Jennifer Lynne Bath

• Chief Financial Officer — Richard Areglado

Need a punctuation from a Motley Fool analyst? Email [email protected]

Jennifer Lynne Bath: Thank you precise much, and bully morning, everyone. This quarter, MindWalk Holdings Corp. reported its 3rd consecutive year-over-year gross summation and precocious 3 pipeline programs toward information readouts. In addition, we precocious signed our archetypal one-year endeavor Lens AI level contract. I volition locomotion you done each of those. On revenue, twelvemonth implicit year, we person grown 3 quarters successful a enactment successful a marketplace wherever pharmaceutical request for AI-driven find is accelerating. On the commercialized model, our largest endeavor AI lawsuit precocious signed a one-year Lens AI level contract, the archetypal of its benignant for us, shifting a portion of our gross from project-based to contracted and recurring.

On our pipeline, dengue, GLP-1, and influenza each person information anticipated successful the adjacent term. Please fto maine instrumentality those successful turn. MindWalk Holdings Corp. conscionable reported its 3rd consecutive 4th of year-over-year gross growth. Revenue was $4,200,000 this quarter, a 52% summation from $2,700,000 successful the aforesaid 4th past year. MindWalk Holdings Corp.'s U.S. revenue, our astir important commercialized market, doubled twelvemonth implicit year. That maturation reflects a deliberate strategical absorption connected the U.S. market. North America is wherever AI-driven find request is concentrated and wherever the regulatory situation is actively pulling pharma toward home partners. We person invested successful U.S. commercialized presence, including concern improvement and income resources successful the Boston and Cambridge area.

Separately, we person besides established biologics services operations successful the Boston and Cambridge area. Both bespeak the aforesaid strategical direction. Our clients are pharmaceutical and biotech organizations with their ain R&D capabilities. They prosecute america erstwhile the situation exceeds what accepted tools tin address. Which brings maine to the 2nd happening I would similar to highlight. Recently, our largest endeavor AI lawsuit signed a one-year Lens AI level contract. This declaration is structured arsenic a recurring gross model, revenues being recognized monthly. To beryllium precise astir wherefore this matters, until now, our gross has been chiefly project-based. Clients prosecute america for a program, we deliver, we invoice.

That exemplary produces bully revenue, but it requires continuous reselling; each 4th starts adjacent to zero. A level declaration is structurally different. It is contracted, recurring, monthly gross that does not necessitate reselling. It delivers worth consistently, which is precisely what Lens AI is designed to do. Lens AI is actively being rolled retired crossed our broader lawsuit base, the one-year declaration is 1 we are scaling. Now let's sermon specifically what Lens AI, powered by HIFT technology, demonstrated this quarter. At its instauration is HIFT, our patented biologic practice strategy that operates connected the invariant functional furniture of the series space. Sequence-based AI tools place patterns successful aboveground similarity.